Xenon Pharmaceuticals
XENE
42 hedge funds and large institutions have $83.6M invested in Xenon Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 6 closing their positions.
169% more capital invested
Capital invested by funds: $31.1M → $83.6M (+$52.5M)
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
29.09% more ownership
Funds ownership: 35.28% → 64.37% (+29%)
20% more funds holding
Funds holding: 35 → 42 (+7)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$7.47M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.97M |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$3M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.8M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
-$1.86M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.42M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.21M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$722K |
| 5 |
IPC
Invesco Private Capital
New York
|
-$578K |
XENE Hedge Fund Activity: Q2 2018 in Review
42 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2018, worth a combined $83.6M — up 169% from $31.1M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new XENE positions and 6 closed out — a net gain of 7 holders — while 9 added to existing stakes and 8 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $7.47M. The largest seller was Nexthera Capital, exiting entirely with an estimated $1.86M sold.
- 42 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2018, up from 35 in Q1 2018.
- Funds reported $83.6M of Xenon Pharmaceuticals stock for Q2 2018, up 169% quarter-over-quarter.
- 13 funds opened new Xenon Pharmaceuticals positions in Q2 2018 and 6 closed out, a net change of +7 holders.
- The largest Xenon Pharmaceuticals buyer in Q2 2018 was Avoro Capital Advisors, an estimated $7.47M added.
- The largest Xenon Pharmaceuticals seller in Q2 2018 was Nexthera Capital, an estimated $1.86M sold.
Based on aggregated 13F filings for Q2 2018.